{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:30:23Z","timestamp":1790037023096,"version":"4.0.1"},"reference-count":76,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T00:00:00Z","timestamp":1461024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["f1000research.com"],"crossmark-restriction":false},"short-container-title":["F1000Res"],"abstract":"<ns4:p>Cholestatic liver diseases are hereditary or acquired disorders with impaired hepatic excretion and enterohepatic circulation of bile acids and other cholephiles. The distinct pathological mechanisms, particularly for the acquired forms of cholestasis, are not fully revealed, but advances in the understanding of the molecular mechanisms and identification of key regulatory mechanisms of the enterohepatic circulation of bile acids have unraveled common and central mechanisms, which can be pharmacologically targeted. This overview focuses on the central roles of farnesoid X receptor, fibroblast growth factor 19, and apical sodium-dependent bile acid transporter for the enterohepatic circulation of bile acids and their potential as new drug targets for the treatment of cholestatic liver disease.<\/ns4:p>","DOI":"10.12688\/f1000research.8012.1","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T10:50:05Z","timestamp":1461063005000},"page":"705","update-policy":"https:\/\/doi.org\/10.12688\/f1000research.crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Recent advances in understanding and managing cholestasis"],"prefix":"10.12688","volume":"5","author":[{"given":"Martin","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trauner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2016,4,19]]},"reference":[{"key":"ref-1","doi-asserted-by":"publisher","first-page":"147-59","DOI":"10.1016\/j.cld.2012.12.002","article-title":"Genetic determinants of cholestasis.","volume":"17","author":"G Hirschfield","year":"2013","journal-title":"Clin Liver Dis."},{"key":"ref-2","doi-asserted-by":"publisher","first-page":"804-16","DOI":"10.3748\/wjg.15.804","article-title":"Bile acids: chemistry, physiology, and pathophysiology.","volume":"15","author":"M Monte","year":"2009","journal-title":"World J Gastroenterol."},{"key":"ref-3","doi-asserted-by":"publisher","first-page":"10713","DOI":"10.1038\/ncomms10713","article-title":"Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.","volume":"7","author":"N Gomez-Ospina","year":"2016","journal-title":"Nat Commun."},{"key":"ref-4","doi-asserted-by":"publisher","first-page":"260-7","DOI":"10.1002\/hep.27240","article-title":"Sodium taurocholate cotransporting polypeptide (SLC10A1) deficiency: conjugated hypercholanemia without a clear clinical phenotype.","volume":"61","author":"F Vaz","year":"2015","journal-title":"Hepatology."},{"key":"ref-5","doi-asserted-by":"publisher","first-page":"1038-45","DOI":"10.1016\/j.jhep.2008.07.027","article-title":"Genetic factors of susceptibility and of severity in primary biliary cirrhosis.","volume":"49","author":"R Poupon","year":"2008","journal-title":"J Hepatol."},{"key":"ref-6","doi-asserted-by":"publisher","first-page":"326-8","DOI":"10.1038\/ng.2918","article-title":"Mutations in TJP2 cause progressive cholestatic liver disease.","volume":"46","author":"M Sambrotta","year":"2014","journal-title":"Nat Genet."},{"key":"ref-7","doi-asserted-by":"publisher","first-page":"574-85","DOI":"10.1038\/ncpgasthep0602","article-title":"Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis.","volume":"3","author":"A Geier","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol."},{"key":"ref-8","doi-asserted-by":"publisher","first-page":"137-74","DOI":"10.1146\/annurev.biochem.72.121801.161712","article-title":"The enzymes, regulation, and genetics of bile acid synthesis.","volume":"72","author":"D Russell","year":"2003","journal-title":"Annu Rev Biochem."},{"key":"ref-9","doi-asserted-by":"publisher","first-page":"565-80","DOI":"10.1016\/j.jhep.2009.05.012","article-title":"New molecular insights into the mechanisms of cholestasis.","volume":"51","author":"M Wagner","year":"2009","journal-title":"J Hepatol."},{"key":"ref-10","doi-asserted-by":"publisher","first-page":"678-93","DOI":"10.1038\/nrd2619","article-title":"Targeting bile-acid signalling for metabolic diseases.","volume":"7","author":"C Thomas","year":"2008","journal-title":"Nat Rev Drug Discov."},{"key":"ref-11","doi-asserted-by":"publisher","first-page":"1035-78","DOI":"10.1002\/cphy.c120027","article-title":"Bile formation and secretion.","volume":"3","author":"J Boyer","year":"2013","journal-title":"Compr Physiol."},{"key":"ref-12","doi-asserted-by":"publisher","first-page":"253-7","DOI":"10.1097\/MOG.0b013e328352aab2","article-title":"The biliary HCO(3)(-) umbrella: experimental evidence revisited.","volume":"28","author":"U Beuers","year":"2012","journal-title":"Curr Opin Gastroenterol."},{"key":"ref-13","doi-asserted-by":"publisher","first-page":"S111-24","DOI":"10.1097\/01.mcg.0000155551.37266.26","article-title":"Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.","volume":"39","author":"M Trauner","year":"2005","journal-title":"J Clin Gastroenterol."},{"key":"ref-14","doi-asserted-by":"publisher","first-page":"217-25","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis.","volume":"2","author":"T Inagaki","year":"2005","journal-title":"Cell Metab."},{"key":"ref-15","doi-asserted-by":"crossref","first-page":"3416-21","DOI":"10.1016\/S0021-9258(19)67810-5","article-title":"Regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat.","volume":"266","author":"W Pandak","year":"1991","journal-title":"J Biol Chem."},{"key":"ref-16","doi-asserted-by":"publisher","first-page":"17-29","DOI":"10.1016\/j.mce.2012.05.004","article-title":"FXR signaling in the enterohepatic system.","volume":"368","author":"T Matsubara","year":"2013","journal-title":"Mol Cell Endocrinol."},{"key":"ref-17","doi-asserted-by":"publisher","first-page":"147-91","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation.","volume":"89","author":"P Lefebvre","year":"2009","journal-title":"Physiol Rev."},{"key":"ref-18","doi-asserted-by":"publisher","first-page":"721-31","DOI":"10.1016\/S1534-5807(02)00187-9","article-title":"Redundant pathways for negative feedback regulation of bile acid production.","volume":"2","author":"L Wang","year":"2002","journal-title":"Dev Cell."},{"key":"ref-19","doi-asserted-by":"publisher","first-page":"789-99","DOI":"10.1016\/j.cell.2006.06.049","article-title":"Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network.","volume":"126","author":"A Bookout","year":"2006","journal-title":"Cell."},{"key":"ref-20","doi-asserted-by":"publisher","first-page":"1352-8","DOI":"10.1038\/nm1138","article-title":"Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.","volume":"10","author":"A Moschetta","year":"2004","journal-title":"Nat Med."},{"key":"ref-21","doi-asserted-by":"publisher","first-page":"1632-43","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.","volume":"48","author":"Y Wang","year":"2008","journal-title":"Hepatology."},{"key":"ref-22","doi-asserted-by":"publisher","first-page":"1383-6","DOI":"10.1002\/hep.22668","article-title":"Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation.","volume":"48","author":"M Wagner","year":"2008","journal-title":"Hepatology."},{"key":"ref-23","doi-asserted-by":"publisher","first-page":"55-66","DOI":"10.1016\/j.jaut.2014.02.010","article-title":"The critical role of myeloid-derived suppressor cells and FXR activation in immune-mediated liver injury.","volume":"53","author":"H Zhang","year":"2014","journal-title":"J Autoimmun."},{"key":"ref-24","doi-asserted-by":"publisher","first-page":"S25-37","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond.","volume":"62","author":"U Beuers","year":"2015","journal-title":"J Hepatol."},{"key":"ref-25","doi-asserted-by":"publisher","first-page":"291-308","DOI":"10.1002\/hep.22906","article-title":"Primary biliary cirrhosis.","volume":"50","author":"K Lindor","year":"2009","journal-title":"Hepatology."},{"key":"ref-26","doi-asserted-by":"publisher","first-page":"CD003626","DOI":"10.1002\/14651858.CD003626.pub2","article-title":"Bile acids for primary sclerosing cholangitis.","author":"G Poropat","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"key":"ref-27","doi-asserted-by":"crossref","first-page":"837-52","DOI":"10.1016\/0016-5085(86)90859-0","article-title":"Effect of side-chain shortening on the physiologic properties of bile acids: hepatic transport and effect on biliary secretion of 23-nor-ursodeoxycholate in rodents.","volume":"90","author":"Y Yoon","year":"1986","journal-title":"Gastroenterology."},{"key":"ref-28","doi-asserted-by":"publisher","first-page":"465-81","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.","volume":"130","author":"P Fickert","year":"2006","journal-title":"Gastroenterology."},{"key":"ref-29","doi-asserted-by":"publisher","first-page":"1972-81","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-\/- mice.","volume":"49","author":"E Halilbasic","year":"2009","journal-title":"Hepatology."},{"key":"ref-30","doi-asserted-by":"publisher","first-page":"140-151.e12","DOI":"10.1053\/j.gastro.2011.09.051","article-title":"Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.","volume":"142","author":"T Moustafa","year":"2012","journal-title":"Gastroenterology."},{"key":"ref-31","doi-asserted-by":"publisher","first-page":"1201-8","DOI":"10.1016\/j.jhep.2013.01.026","article-title":"Differential effects of norUDCA and UDCA in obstructive cholestasis in mice.","volume":"58","author":"P Fickert","year":"2013","journal-title":"J Hepatol."},{"key":"ref-32","doi-asserted-by":"publisher","first-page":"433-9","DOI":"10.1159\/000371904","article-title":"Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.","volume":"33","author":"M Trauner","year":"2015","journal-title":"Dig Dis."},{"key":"ref-33","doi-asserted-by":"publisher","first-page":"3569-72","DOI":"10.1021\/jm025529g","article-title":"6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.","volume":"45","author":"R Pellicciari","year":"2002","journal-title":"J Med Chem."},{"key":"ref-34","doi-asserted-by":"publisher","first-page":"604-12","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.","volume":"313","author":"S Fiorucci","year":"2005","journal-title":"J Pharmacol Exp Ther."},{"key":"ref-35","doi-asserted-by":"publisher","first-page":"1303-12","DOI":"10.1002\/hep.24537","article-title":"Dual farnesoid X receptor\/TGR5 agonist INT-767 reduces liver injury in the Mdr2-\/- (Abcb4-\/-) mouse cholangiopathy model by promoting biliary HCO-3 output.","volume":"54","author":"A Baghdasaryan","year":"2011","journal-title":"Hepatology."},{"key":"ref-36","doi-asserted-by":"publisher","first-page":"1678-87","DOI":"10.1172\/JCI18945","article-title":"Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.","volume":"112","author":"Y Liu","year":"2003","journal-title":"J Clin Invest."},{"key":"ref-37","doi-asserted-by":"publisher","first-page":"355-65","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis.","volume":"142","author":"S Modica","year":"2012","journal-title":"Gastroenterology."},{"key":"ref-38","doi-asserted-by":"publisher","first-page":"159-65","DOI":"10.1038\/nm.3760","article-title":"Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance.","volume":"21","author":"S Fang","year":"2015","journal-title":"Nat Med."},{"key":"ref-39","doi-asserted-by":"publisher","first-page":"751-61.e8","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.","volume":"148","author":"G Hirschfield","year":"2015","journal-title":"Gastroenterology."},{"key":"ref-40","doi-asserted-by":"publisher","first-page":"956-65","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.","volume":"385","author":"B Neuschwander-Tetri","year":"2015","journal-title":"Lancet."},{"key":"ref-41","doi-asserted-by":"publisher","first-page":"704-6","DOI":"10.1053\/j.gastro.2015.02.037","article-title":"Targeting the FXR nuclear receptor to treat liver disease.","volume":"148","author":"B Neuschwander-Tetri","year":"2015","journal-title":"Gastroenterology."},{"key":"ref-42","doi-asserted-by":"publisher","first-page":"S525-S526","DOI":"10.1016\/S0168-8278(14)61463-X","article-title":"O168 the first primary biliary cirrhosis (PBC) phase 3 trial in two decades \u2013 an international study of the FXR agonist obeticholic acid in PBC patients.","volume":"60","author":"F Nevens","year":"2014","journal-title":"J Hepatol."},{"key":"ref-43","first-page":"511A (Abstract)","article-title":"Sustained improvement in the markers of cholestasis in an open label long term safety extension study of obeticholic acid in primary biliary cirrhosis patients.","volume":"62","author":"M Trauner","year":"2015","journal-title":"Hepatology."},{"key":"ref-44","doi-asserted-by":"publisher","DOI":"10.1038\/srep13462","article-title":"Expression of hepatic Fibroblast Growth Factor 19 is enhanced in Primary Biliary Cirrhosis and correlates with severity of the disease.","volume":"5","author":"E Wunsch","year":"2015","journal-title":"Sci Rep."},{"key":"ref-45","doi-asserted-by":"publisher","first-page":"575-83","DOI":"10.1002\/hep.24702","article-title":"The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.","volume":"55","author":"S Zweers","year":"2012","journal-title":"Hepatology."},{"key":"ref-46","doi-asserted-by":"publisher","first-page":"247ra100","DOI":"10.1126\/scitranslmed.3009098","article-title":"A nontumorigenic variant of FGF19 treats cholestatic liver diseases.","volume":"6","author":"J Luo","year":"2014","journal-title":"Sci Transl Med."},{"key":"ref-47","doi-asserted-by":"publisher","first-page":"2295-307","DOI":"10.1016\/S0002-9440(10)61177-7","article-title":"A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice.","volume":"160","author":"K Nicholes","year":"2002","journal-title":"Am J Pathol."},{"key":"ref-48","doi-asserted-by":"publisher","first-page":"347-58","DOI":"10.1016\/j.ccr.2011.01.040","article-title":"Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.","volume":"19","author":"E Sawey","year":"2011","journal-title":"Cancer Cell."},{"key":"ref-49","doi-asserted-by":"publisher","first-page":"914-29","DOI":"10.1002\/hep.28257","article-title":"Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2-deficient mice.","volume":"63","author":"M Zhou","year":"2016","journal-title":"Hepatology."},{"key":"ref-50","first-page":"263A (Abstract)","article-title":"NGM282, A Novel Variant of FGF-19, Demonstrates Biologic Activity in Primary Biliary Cirrhosis Patients with an Incomplete Response to Ursodeoxycholic Acid: Results of a Phase 2 Multicenter, Randomized, Double Blinded, Placebo Controlled Trial.","volume":"62","author":"M Mayo","year":"2015","journal-title":"Hepatology."},{"key":"ref-51","doi-asserted-by":"publisher","first-page":"1621-4","DOI":"10.1126\/science.1198363","article-title":"FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis.","volume":"331","author":"S Kir","year":"2011","journal-title":"Science."},{"key":"ref-52","doi-asserted-by":"publisher","first-page":"1189-94","DOI":"10.1016\/j.cgh.2009.04.024","article-title":"A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis.","volume":"7","author":"J Walters","year":"2009","journal-title":"Clin Gastroenterol Hepatol."},{"key":"ref-53","doi-asserted-by":"publisher","first-page":"426-34","DOI":"10.1038\/nrgastro.2014.32","article-title":"Bile acid diarrhoea and FGF19: new views on diagnosis, pathogenesis and therapy.","volume":"11","author":"J Walters","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol."},{"key":"ref-54","doi-asserted-by":"publisher","first-page":"22-9","DOI":"10.1016\/j.tem.2014.10.002","article-title":"Tissue-specific actions of the metabolic hormones FGF15\/19 and FGF21.","volume":"26","author":"B Owen","year":"2015","journal-title":"Trends Endocrinol Metab."},{"key":"ref-55","doi-asserted-by":"publisher","first-page":"603-10","DOI":"10.1517\/13543784.2015.1006357","article-title":"Fibroblast growth factor 19-targeted therapies for the treatment of metabolic disease.","volume":"24","author":"J Rysz","year":"2015","journal-title":"Expert Opin Investig Drugs."},{"key":"ref-56","doi-asserted-by":"publisher","first-page":"33920-7","DOI":"10.1074\/jbc.M306370200","article-title":"Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice.","volume":"278","author":"P Dawson","year":"2003","journal-title":"J Biol Chem."},{"key":"ref-57","doi-asserted-by":"publisher","first-page":"e37787","DOI":"10.1371\/journal.pone.0037787","article-title":"Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice.","volume":"7","author":"T Lund\u00e5sen","year":"2012","journal-title":"PLoS One."},{"key":"ref-58","doi-asserted-by":"publisher","first-page":"140; author reply 140-1","DOI":"10.1038\/ajg.2011.378","article-title":"Altered bile acid pool using IBAT inhibitors for constipation: a potentially increased risk of malignancy.","volume":"107","author":"P Trivedi","year":"2012","journal-title":"Am J Gastroenterol."},{"key":"ref-59","doi-asserted-by":"publisher","first-page":"1193-200","DOI":"10.1093\/carcin\/bgv107","article-title":"Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.","volume":"36","author":"J Raufman","year":"2015","journal-title":"Carcinogenesis."},{"key":"ref-60","doi-asserted-by":"publisher","first-page":"512-23","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.","volume":"63","author":"A Miethke","year":"2016","journal-title":"Hepatology."},{"key":"ref-61","doi-asserted-by":"publisher","first-page":"674-81","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.","volume":"64","author":"A Baghdasaryan","year":"2016","journal-title":"J Hepatol."},{"key":"ref-62","first-page":"612A (Abstract)","article-title":"The ileal bile acid transporter inhibitor A4250 modulates bile acid synthesis and decreases serum bile acids.","volume":"62","author":"H Marschall","year":"2015","journal-title":"Hepatology."},{"key":"ref-63","doi-asserted-by":"publisher","first-page":"47C-55C","DOI":"10.1016\/j.amjcard.2006.11.022","article-title":"Safety considerations with gastrointestinally active lipid-lowering drugs.","volume":"99","author":"T Jacobson","year":"2007","journal-title":"Am J Cardiol."},{"key":"ref-64","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/srep00430","article-title":"TGR5 potentiates GLP-1 secretion in response to anionic exchange resins.","volume":"2","author":"T Harach","year":"2012","journal-title":"Sci Rep."},{"key":"ref-65","doi-asserted-by":"publisher","first-page":"3920-5","DOI":"10.1073\/pnas.0509592103","article-title":"Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor.","volume":"103","author":"T Inagaki","year":"2006","journal-title":"Proc Natl Acad Sci U S A."},{"key":"ref-66","doi-asserted-by":"publisher","first-page":"1283-92","DOI":"10.1016\/j.jhep.2012.01.019","article-title":"Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease.","volume":"56","author":"D Fouts","year":"2012","journal-title":"J Hepatol."},{"key":"ref-67","doi-asserted-by":"publisher","first-page":"1931-41","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.","volume":"57","author":"A Honda","year":"2013","journal-title":"Hepatology."},{"key":"ref-68","doi-asserted-by":"publisher","first-page":"539-47","DOI":"10.1042\/BJ20020981","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha)-mediated regulation of multidrug resistance 2 (Mdr2) expression and function in mice.","volume":"369","author":"T Kok","year":"2003","journal-title":"Biochem J."},{"key":"ref-69","doi-asserted-by":"publisher","first-page":"1813-25","DOI":"10.1194\/jlr.M400132-JLR200","article-title":"Bezafibrate stimulates canalicular localization of NBD-labeled PC in HepG2 cells by PPARalpha-mediated redistribution of ABCB4.","volume":"45","author":"J Shoda","year":"2004","journal-title":"J Lipid Res."},{"key":"ref-70","doi-asserted-by":"publisher","first-page":"1023-34","DOI":"10.1002\/hep.24148","article-title":"Nuclear receptors in liver disease.","volume":"53","author":"M Wagner","year":"2011","journal-title":"Hepatology."},{"key":"ref-71","first-page":"695-709","article-title":"Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.","volume":"118","author":"F Arenas","year":"2008","journal-title":"J Clin Invest."},{"key":"ref-72","doi-asserted-by":"publisher","first-page":"558-66","DOI":"10.1002\/hep.27767","article-title":"Targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2: Evidence for improvement of cholestasis with 4-phenylbutyrate.","volume":"62","author":"E Gonzales","year":"2015","journal-title":"Hepatology."},{"key":"ref-73","doi-asserted-by":"publisher","first-page":"695-8","DOI":"10.1016\/j.jhep.2012.04.017","article-title":"Successful mutation-specific chaperone therapy with 4-phenylbutyrate in a child with progressive familial intrahepatic cholestasis type 2.","volume":"57","author":"E Gonzales","year":"2012","journal-title":"J Hepatol."},{"key":"ref-74","doi-asserted-by":"publisher","first-page":"5070-8","DOI":"10.1074\/jbc.M111.275438","article-title":"Effects of cellular, chemical, and pharmacological chaperones on the rescue of a trafficking-defective mutant of the ATP-binding cassette transporter proteins ABCB1\/ABCB4.","volume":"287","author":"J Gautherot","year":"2012","journal-title":"J Biol Chem."},{"key":"ref-75","doi-asserted-by":"publisher","first-page":"286-96","DOI":"10.1002\/hep.23268","article-title":"Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate.","volume":"51","author":"L van der Velden","year":"2010","journal-title":"Hepatology."},{"key":"ref-76","doi-asserted-by":"publisher","first-page":"1846-9","DOI":"10.1016\/j.jpedsurg.2015.07.016","article-title":"Total biliary diversion as a treatment option for patients with progressive familial intrahepatic cholestasis and Alagille syndrome.","volume":"50","author":"W van der Woerd","year":"2015","journal-title":"J Pediatr Surg."}],"container-title":["F1000Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/f1000research.com\/articles\/5-705\/v1\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-705\/v1\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/f1000research.com\/articles\/5-705\/v1\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T23:24:22Z","timestamp":1655508262000},"score":1,"resource":{"primary":{"URL":"https:\/\/f1000research.com\/articles\/5-705\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,19]]},"references-count":76,"URL":"https:\/\/doi.org\/10.12688\/f1000research.8012.1","relation":{"has-review":[{"id-type":"doi","id":"10.5256\/f1000research.8621.r13473","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8621.r13474","asserted-by":"subject"},{"id-type":"doi","id":"10.5256\/f1000research.8621.r13474","asserted-by":"object"},{"id-type":"doi","id":"10.5256\/f1000research.8621.r13473","asserted-by":"object"}]},"ISSN":["2046-1402"],"issn-type":[{"value":"2046-1402","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,19]]},"assertion":[{"value":"Indexed","URL":"https:\/\/f1000research.com\/articles\/5-705\/v1#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.5256\/f1000research.8621.r13474, Keith Lindor, College of Health Solutions, Arizona State University, Tempe, AZ, 85281, USA, 19 Apr 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-705\/v1#referee-response-13474","order":0,"name":"referee-response-13474","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.5256\/f1000research.8621.r13473, Saul Karpen, Emory University School of Medicine, Atlanta, GA, 30307, USA, 19 Apr 2016, version 1, indexed","URL":"https:\/\/f1000research.com\/articles\/5-705\/v1#referee-response-13473","order":1,"name":"referee-response-13473","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by grants F3008-B19 and F3517-B20 (to Michael Trauner) from the Austrian Science Foundation.","order":2,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}